The collectin pentraxin 3 (PTX3) is an essential component of host resistance to pulmonary aspergillosis. Here we examined the protective effects of administration of PTX3 alone or together with deoxycholate amphotericin B (Fungizone) or liposomal amphotericin B (AmBisome) against invasive aspergillosis in a murine model of allogeneic bone marrow transplantation. PTX3, alone or in combination with the polyenes, was given intranasally or parenterally either before, in concomitance with, or after the intranasal infection with Aspergillus fumigatus conidia. Mice were monitored for resistance to infection and parameters of innate and adaptive T-helper immunity. The results showed the following: (i) complete resistance to infection and reinfection was observed in mice treated with PTX3 alone; (ii) the protective effect of PTX3 was similar or superior to that observed with liposomal amphotericin B or deoxycholate amphotericin B, respectively; (iii) protection was associated with accelerated recovery of lung phagocytic cells and T-helper-1 lymphocytes and concomitant decrease of inflammatory pathology; and (iv) PTX3 potentiated the therapeutic efficacy of suboptimal doses of either antimycotic drug. Together, these data suggest the potential therapeutic use of PTX3 either alone or as an adjunctive therapy in A. fumigatus infections.

Gaziano, R., Bozza, S., Bellocchio, S., Perruccio, K., Montagnoli, C., Pitzurra, L., et al. (2004). Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 48(11), 4414-4421 [10.1128/AAC.48.11.4414-4421.2004].

Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals

GAZIANO, ROBERTA;
2004-11-01

Abstract

The collectin pentraxin 3 (PTX3) is an essential component of host resistance to pulmonary aspergillosis. Here we examined the protective effects of administration of PTX3 alone or together with deoxycholate amphotericin B (Fungizone) or liposomal amphotericin B (AmBisome) against invasive aspergillosis in a murine model of allogeneic bone marrow transplantation. PTX3, alone or in combination with the polyenes, was given intranasally or parenterally either before, in concomitance with, or after the intranasal infection with Aspergillus fumigatus conidia. Mice were monitored for resistance to infection and parameters of innate and adaptive T-helper immunity. The results showed the following: (i) complete resistance to infection and reinfection was observed in mice treated with PTX3 alone; (ii) the protective effect of PTX3 was similar or superior to that observed with liposomal amphotericin B or deoxycholate amphotericin B, respectively; (iii) protection was associated with accelerated recovery of lung phagocytic cells and T-helper-1 lymphocytes and concomitant decrease of inflammatory pathology; and (iv) PTX3 potentiated the therapeutic efficacy of suboptimal doses of either antimycotic drug. Together, these data suggest the potential therapeutic use of PTX3 either alone or as an adjunctive therapy in A. fumigatus infections.
nov-2004
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Con Impact Factor ISI
Aspergillus fumigatus; Recurrence; Aspergillosis; Th1 Cells; Mice, Inbred C3H; Lung; Animals; Serum Amyloid P-Component; Flow Cytometry; Bone Marrow Transplantation; Antifungal Agents; Amphotericin B; Mice; Cytokines; Enzyme-Linked Immunosorbent Assay; Mice, Inbred BALB C; Drug Combinations; C-Reactive Protein
Gaziano, R., Bozza, S., Bellocchio, S., Perruccio, K., Montagnoli, C., Pitzurra, L., et al. (2004). Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 48(11), 4414-4421 [10.1128/AAC.48.11.4414-4421.2004].
Gaziano, R; Bozza, S; Bellocchio, S; Perruccio, K; Montagnoli, C; Pitzurra, L; Salvatori, G; De Santis, R; Carminati, P; Mantovani, A; Romani, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
AAC.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 304.19 kB
Formato Adobe PDF
304.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/29354
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 125
  • ???jsp.display-item.citation.isi??? 112
social impact